TAMSULOSİN KULLANIMINA BAĞLI OLARAK GELİŞEN İNTRAOPERATİF FLOPPY İRİS SENDROMU (İFİS): ÜROLOJİK YAKLAŞIM

Year 2008, Volume: 21 Issue: 3, 275 - 281, 24.06.2015

Kenan Isen , Uğur Keklikçi

Abstract

İntraoperatif floppy iris sendromu(İFİS) benign prostat hiperplazisi nedeniyle tamsulosin kullanan ve katarakt cerrahisi uygulanan hastalarda tanımlanmış yeni bir sendromdur. Bu sendrom gevşek iris, kornea kesi giriş yerlerinden sürekli prolobe olmaya eğilimi olan iris ve operasyon sırasında ani ve progresif pupiller miyozis gelişmesi ile karakterizedir. Bütün bu durumlar intraoperatif komplikasyon gelişme riskini arttırmaktadır. Cerrahi sırasında oluşabilecek komplikasyonları azaltmak için hastanın halen yada geçmişte alfa-1 bloker kullanıp kullanmadığı göz hastalıkları uzmanı tarafından bilinmelidir. Üroloji uzmanı alfa-1 bloker yazma alışkanlığını değiştirmemeli. Bununla birlikte, bir selektif alfa-1 bloker reçetelenirken hastada katarakt olup olmadığı ve cerrahi planlanlanıp planlanmadığı göz önünde bulundurmalıdır.

Keywords

Tamsulosin, Katarakt cerrahisi, Benign prostat hiperplazisi, Komplikasyonlar

References

• 1. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005; 31:664-673.
• 2. Chadha V, Borooah S, Tey A, Styles C, Singh J. Floppy iris behaviour during cataract surgery: associations and variations. Br J Ophthalmol 2007; 91:40-42.
• 3. Blouin MC, Blouin J, Perreault S, Lapointe A, Dragomir A. Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: comparison of tamsulosin and alfuzosin. J Cataract Refract Surg 2007; 33:1227-1234.
• 4. Oshika T, Ohashi Y, Inamura M, et al. Incidence of intraoperative floppy Iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist. Am J Ophthalmol 2007; 143:150-151.
• 5. Andersson KE. Alpha-adrenoreceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoreceptor antagonists. World J Urol 2002; 19:390-396.
• 6. Schwinn DA, Afshari NA. Alpha(1)-Adrenergic receptor antagonists and the iris: new mechanistic insights into floppy iris syndrome. Surv Ophthalmol 2006; 51:501-512.
• 7. Chang DF, Osler RH, Wang L, Koch DD. Prospective multicenter evaluation of cataract surgery in patients taking tamsulosin(Flomax). Ophthalmology 2007; 114:957-964.
• 8. Gurbaxani A, Packard R. Intracameral phenylephrine to prevent floppy iris syndrome during cataract surgery in patients on tamsulosin. Eye 2007; 21:331-332.
• 9. Shugar JK. Use of epinephrine for IFIS prophylaxis. J Cataract Refract Surg 2006;32:1074-1075.
• 10. Bendel RE, Phillips MB.Preoperative use of atropine to prevent intraoperative floppy iris syndrome in patients taking tamsulosin. J Cataract Refract Surg 2006; 32:1603-1605.
• 11. Masket S, Belani S. Combined preoperative topical atropine sulfate 1% and intracameral nonpreserved epinephrine hydrochloride 1:4000 for management of intraoperative floppy-iris syndrome. J Cataract Refract Surg 2007; 33:580-582.
• 12. Colvard DM, Kandavel R. Viscoelastic solutions to challenging surgeries. Rev Ophthalmol 2006; 13:1-3.
• 13. Takmaz T, Can I.Intraoperative floppy-iris syndrome: do we know everything about it? J Cataract Refract Surg 2007;33:1110-1112.
• 14. Takmaz T, Can I. Clinical features, complications, and incidence of intraoperative floppy iris syndrome in patients taking tamsulosin. Eur J Ophthalmol 2007;17:909-913.
• 15. Yaycıoğlu R, Yaycıoğlu O, Gul U, Pelit A, Adıbelli FM, Akova A. The effect of two systemic alpha-1 adrenergic blockers on pupil diameter: a prospective randomized single-blind study. Naunyn- Schmiedeberg’s Arch Pharmacol 2007; 375:199-203.
• 16. Schwing DA, Asfari NA.: Alpha(1)-adrenergic receptor antagonists and the iris: new mechanistic insights into Floppy Iris Syndrome. Surv Ophthalmol 2006; 51:501- 512.
• 17. Pianka P, Oron Y, Lazar M, Gever O. Nonadrenergic, noncholinergic relaxation of bovine iris sphincter: role of endogeneous nitric oxide. Invest Ophthalmol Vis Sci 2000; 41: 880-886.
• 18. De la Rosette J, Madersbacher S, Alivizatos G: EAU guidelines on benign prostatic hyperplasia. Eur Urol 2004; 46:547-554.
• 19. Roehrborn CG, McConnell JD, Barry MJ, et al: AUA guidelines on the management of benign prostatic hyperplasia(BPH). J Urol 2003; 170: 530-547.
• 20. Leonardini A, Hiebel JB, Guarneri , et al. Pharmalogical characterization of uroselective alpha1 antagonist rec. 15/2739(SB 216469): role of the alpha 1L adrenoreceptor in tissue selectivity, part 1. J Pharmacol Exp Ther 1997; 281:1272-1293.
• 21. Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G. Use of recombinant alpha-1 adrenoreceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995; 288; 201-207.
• 22. Roehrborn CG, Schwinn DA.: Alpha1-adrenergicibitors receptors and their inhibitors in lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2004; 171: 1029-1035.
• 23. Cheung CM, Awan MA, Sandramouli S. Prevalence and clinical findings of tamsulosin-associated intraoperative floppy-iris syndrome. J Cataract Refract Surg 2006; 32:1336-1339.
• 24. Küpeli B, Irklita L, Gürocak S, et al.. Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy? Urology 2004; 64:1111-1115.
• 25. 25. Lee SW, Liong ML, Yuen KH, Liong YV, Krieger JN. Chronic prostatitis/chronic pelvic pain syndrome: role of alpha blocker therapy. Urol Int 2007; 78:97- 105.
• 26. Sinha D, Arunkalaivanan A. Urethral syndrome: response to alpha-adrenergic blocking agents. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:659-660.
• 27. Lawrentschuk N, .Bylsma GW. Intraoperative ‘floppyiris’ syndrome and its relationship to tamsulosin: a urologist’s guide. BJU Int 2006; 97:2-4.